7/22/22 – Weekly Covid-19 Update

CHAP’s COVID-19 Weekly Update
In this “one-stop-shop” update, CHAP will provide a roundup of important COVID-19 information from various federal sources.

All health care providers should be monitoring COVID-19 incidence rates in their state/county on an ongoing basis.  The Centers for Disease Control and Prevention CDC provides weekly data about case rates, deaths, testing, and vaccine administration on their COVID tracker webpage.


CDC Data



COVID-19 Variants by region



Variant Types – Map key

US Variants Key


CDC and other Federal Updates: 

COVID-19 Public Health Emergency (PHE) Extended
The current COVID-19 PHE declaration was extended another 90 days and will expire on 10/13/22.  All CMS waivers remain in place. 

FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted (FDA, 7/13/22)
The FDA issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The Novavax COVID-19 Vaccine, Adjuvanted is administered as a two-dose primary series, three weeks apart. The vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant. Adjuvants are incorporated into some vaccines to enhance the immune response of the vaccinated individual. The authorization offers adults in the United States who have not yet received a COVID-19 vaccine another option 

SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests (FDA, 7/14/22)
This webpage provides information about tests authorized by the U.S. Food and Drug Administration (FDA) for the identification and differentiation of specific SARS-CoV-2 mutations and lineages as well as the impact of viral mutations on COVID-19 tests. 

FDA Updates (7/19/22)